Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05749549 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase I/IIa Study of BR1733 in Subjects With Advanced Cancers

StatusUnknown
PhasePhase 1/2
Started2023-04-19
View on ClinicalTrials.gov ↗
Record status
This record was last updated August 7, 2024 (before its estimated May 2025 completion). Its status may not reflect the trial's current state.
This study is a Phase I/IIa, multi-center, open-label study of BR1733 with a dose escalation part followed by a dose expansion part in adult subjects with advanced cancers. This treatment to characterize the safety, tolerability, PK, PD and preliminary antitumor activity. The study treatment will be administered until the subject experiences unacceptable toxicity, progressive disease, and/or has treatment discontinued at the discretion of the Investigator or the subject, or due to withdrawal of consent.

Amendment history 1 change detected by DataLookout

2026-09-06
Trial status changed: Active, Not Recruiting → Unknown
Trial Details
NCT Number NCT05749549
Lead Sponsor Shanghai Blueray Biopharma Co., Ltd.
Conditions Advanced Cancer, Follicular Lymphoma, Peripheral T Cell Lymphoma, Diffuse Large B Cell Lymphoma
Enrollment 191 participants
Start Date 2023-04-19
Primary Completion 2025-05 (estimated)
Study Completion 2026-05 (estimated)
Updated on ClinicalTrials.gov 2024-08-07